Market Overview

Independent Study Shows Effectiveness of Covidien's Blood Clot Prevention Technology

Share:

Covidien
(NYSE: COV), a leading global provider of healthcare products, today
announced that an independent study conducted by the University of
Edinburgh has successfully demonstrated the effectiveness of Covidien's
Kendall SCD™ system with Vascular Refill Detection Technology on
immobile stroke patients.

An independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien's Kendall SCD(TM) system with Vascular Refill Detection Technology on immobile stroke patients. (Photo: Business Wire)

The results of the CLOTS 3 trial were presented at the European
Stroke Conference by Professor Martin S. Dennis of the University of
Edinburgh's Division of Clinical Neurosciences and also published in The
Lancet. The new study showed a 29.9% decrease in the development

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (COV)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→